PROfound Puts Lynparza On Track For Prostate Cancer Indication

 
• By Sten Stovall

AstraZeneca and Merck & Co said their PARP inhibitor Lynparza has become the first to show positive Phase III trial data in metastatic castration-resistant prostate cancer, putting pressure on rival Clovis’s Rubraca.

Cancer_Cell
Lynparza could become the first PARP inhibitor in prostate cancer. • Source: Shutterstock

More from Clinical Trials

More from R&D